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Abstract
Background: Genomic risk information, based on common genomic susceptibility variants associated with risk of
complex diseases such as cancer, may be incorporated into personalised prevention and screening strategies. We
aimed to engage with members of the public, who are important stakeholders in this process, to further inform
program development and other implementation outcomes such as acceptability and appropriateness.
Methods: Semi-structured interviews were undertaken with 30 participants (aged 24–69 years, 50% female)
recruited from a pilot trial in which they received personalised genomic risk information for melanoma. We
explored participants’ views and attitudes towards offering general personal genomic risk information to the
broader population. The data were analysed thematically.
Results: Two overarching themes relevant to implementation considerations were identified. Firstly, participants’
preferences for accepting an offer of genomic risk information were based on family history, disease incidence and
the possibility of prevention. Secondly, participants felt that the processes for offering risk information should be
based on individual preferences, triaged according to risk and be supported by a health professional trained in
genomics.
Conclusions: Participants felt that offering personal genomic risk information to the general population to inform
prevention and early detection recommendations is acceptable, particularly for common, complex conditions such
as cancer. Understanding participants’ preferences for receiving genomic risk information will assist with
communication strategies and health workforce planning. We anticipate that these findings will contribute to the
development of implementation strategies for incorporating genomic risk information into routine clinical practice.
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Background
Precision public health strategies aim to personalise pre-
vention and screening recommendations by integrating
individual risk assessments [1, 2]. Genomic risk informa-
tion, based on common genomic susceptibility variants
associated with the risk of complex diseases such as can-
cer, may be incorporated into individual risk assessment
[3–6]. There is an important need to examine the effi-
cacy, cost-effectiveness and ethical considerations prior
to offering genomic risk information to the population
[1, 7, 8]. Alongside this, evidence on implementation
considerations will be essential to ensure effective and
appropriate research translation [1, 9, 10].
The Consolidated Framework for Implementation Re-
search (CFIR) enables the identification of determinants
of implementation that are relevant to specific innova-
tions or changes to healthcare systems and pathways
[11, 12]. The CFIR has been adapted to create the Gen-
omic Medicine Implementation Model that aims to
evaluate the implementation of genomic medicine inter-
ventions in clinical practice [13]. In the context of popu-
lation genomic testing for risk of cancer and other
diseases, individuals’ expectations and preferences for re-
ceiving genomic risk information may impact the clinical
and personal utility of integrating genomic risk informa-
tion into prevention and early detection strategies [14].
Further, substantive engagement with relevant stake-
holders such as the public can improve program devel-
opment and other implementation outcomes such as
acceptability and appropriateness [7, 15].
Several studies have examined the public’s views to-
wards personal genomic testing via commercial direct-to-
consumer providers [16, 17]. But there is limited research
on the public’s attitudes, expectations and preferences for
the provision of personal genomic risk information as part
of population prevention and screening strategies, beyond
breast cancer [18]. The aim of this research study was to
address this research gap using qualitative interview meth-
odology, one of the recommended approaches to measure
CFIR constructs [13].
Methods
Recruitment
This is a sub-study of a pilot randomised control trial
that examined the feasibility and acceptability of provid-
ing personalized genomic risk of melanoma to the public
[19]. Participants in the trial were recruited via the Can-
cer Council New South Wales ‘Join a Research Study’
database. Participants (intervention and waitlist control)
in the trial received personal genomic risk of melanoma
information, a phone call from a genetic counsellor and
educational information on melanoma prevention and
early detection. On completion, 30 participants (of 41 in-
vited) took part in a semi-structured interview.
Participants were purposively sampled, ensuring different
genders, ages and genomic risk (low, average, high) results
were included. Ethics approval was obtained from The Uni-
versity of Sydney and participants gave informed consent.
The conduct, design and reporting of this study follows the
Standards for Reporting Qualitative Research [20].
Data collection: semi-structured interviews
An interview guide was developed specifically for the
broader qualitative substudy. This included a range of
questions related to participants’ experiences in the pilot
trial, and a subset of questions that explored their views
on offering the type of melanoma risk information they
received to the general population. This paper focuses
on participant responses and discussion related to their
attitudes, expectations and preferences towards offering
genomic risk information for melanoma and other dis-
eases to the broader population (see Additional file 1 for
the subset of interview questions that are specific to
these aspects). Results on the other data collected in the
broader qualitative substudy (including the other subsets
of questions in the interview guide from the broader
study) have been published elsewhere [21, 22]. The
interview guide was piloted with consumers and other
researchers. The interviews were conducted by AKS,
audio-recorded and transcribed.
Data analysis: qualitative thematic analysis
We conducted thematic analysis, which involved devel-
oping a coding framework using a hybrid (deductive and
inductive) approach; i.e. the transcript data were coded
according to broad top-level categories that matched key
topics in the interview guide, then we searched for pat-
terns and ideas within the top-level categories and fur-
ther coded the data into sub-categories and themes,
which were developed inductively [23–25]. Throughout
the coding process, the research team with diverse areas
of expertise (implementation science, sociology, bioeth-
ics, and cancer epidemiology) discussed the coding
which enabled critical reflection on the developing
themes. Interviews continued until no new themes or
ideas were identified in the data (i.e. data saturation was
reached) [23]. Coding was undertaken by AKS, and
GRM. Agreement between coders was high and discrep-
ancies were discussed until consensus was reached.
NVivo11 (QSR International) was used to facilitate the
coding process.
Results
Participants
The characteristics of the 30 participants interviewed are
show in in Table 1. The mean length of the broader in-
terviews was 32 min (range 14–57 min), but only a por-
tion of the broader interview time was specific to
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implementation considerations. Overarching themes spe-
cific to implementation considerations were identified in the
thematic analysis, which related to preferences and rationale for
offering genomic risk information and the mode of delivery.
Themes
1. Preferences for receiving genomic risk information
are based on family history, disease incidence and
the possibility of prevention
Most participants reported that they would be inter-
ested in receiving personal genomic risk information,
similar to the information they received in the pilot trial,
for other conditions if it were available:
“If there was a general program the public can be in-
formed about their likelihood of having or becoming
ill by one cause or another, yes.” (Female, low gen-
omic risk)
When prompted to reflect on why they would choose
to receive genomic risk information for certain condi-
tions, three sub-themes were identified:
1.1.Family history is a prompt
Family history of disease(s) was identified by many
participants as a motivating factor to obtain personal
genomic risk information because they were interested
in understanding the genetic heritability of a disease,
and how this related to their own risk.
“I’m just sort of thinking about things where there is
a strong family history (…) I guess mental illness
particularly, depression, because that runs in the
family as well. So I’d be interested to see what the
genetic component is around that.” (Female, average
genomic risk)
1.2.Common conditions are preferred
Participants reported preferences for receiving gen-
omic risk information for conditions (primarily cancers)
that they perceived to be common in the population and
relevant to their gender and age groups:
“[I would be interested in] things like bowel cancer and
(…) prostate cancer. I guess they’re the couple of the big
ones aren’t they?” (Male, average genomic risk)
1.3.Possibilities for disease prevention is a motivation
Another reason to obtain genomic risk information
was the possibility of disease prevention through im-
proved health-related behaviours:
“I think that would be really good [to receive this
type of information]. I guess if that other cancer is
preventable, then you can try and change your be-
haviour or even if it’s not (…) there’s always some-
thing you can do, but I think just being aware of
your risks, I guess you can look out for signs.” (Fe-
male, low genomic risk)
2. Processes for providing the genomic risk
information should be based on individual
preferences and be perceived as trustworthy
Regarding how personal genomic risk information is
presented to recipients, participants felt that individuals
should be able to elect to receive it online or via postal
mail as long as these options were secure:
“I would think that in the future that the informa-
tion should be available electronically to people, by
email or by able to be logging into a secure website.
But the option there, of course, for people who still
would like to receive it through the old fashioned
way [via postal mail].” (Male, low genomic risk)
Two subthemes were identified within this broader
theme:
Table 1 Qualitative interview participant characteristics
Characteristic Interviews (n = 30)
Age, mean (range) 53 (24–69)
Female, N (%) 15 (50%)
Highest level of education
High school or equivalent 7 (23%)
Trade/diploma 9 (30%)
University degree or higher 14 (47%)
Genomic risk category, N, (%)
High 12 (40%)
Average 8 (27%)
Low 10 (33%)
Interview conducted via:
Telephone 27 (90%)
Face-to-face 3 (10%)
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2.1.Triaged strategies for health professional
involvement
Participants’ views on the level of health professional
involvement in providing personal genomic risk infor-
mation to the public varied. But most agreed that a
health professional should be involved, at least as a point
of contact:
“I think people should, if they can have the option or if
it comes through their general practitioner. Through
some profession, I don’t think it should be some site that
you just log in and you send off your DNA. I think it’s
good to have that personal contact as well and advice
from a professional.” (Female, average genomic risk)
Many participants described triaged approaches for
health professional contact according to individual risk:
“Maybe you could have a two-tier approach to that,
where people who are average or below the average
risk, they get the opportunity to ring someone and
perhaps people who come back as a higher or a high
risk get a call.” (Male, low genomic risk)
2.2.Health professionals should be equipped to provide
genomic risk information Many participants felt
that a general practitioner (GP) could provide
straightforward genomic risk information. But if the
information was more complex, a genetic
counsellor should be involved.
“I mean if GPs are just giving sort of just a general risk
rating and some guidance on ways to change their be-
haviour, things to do, et cetera, then you probably
don’t need a genetic counsellor involved; the GP can
probably handle it.” (Female, high genomic risk)
Some felt that GPs would be more accessible than
genetic counsellors, in terms of physical access and costs
to the individual:
“I think if you want some more access, I guess, people
are more likely to go to a GP than maybe - but then
if it’s not something that’s for the public, it’s more
like, I don’t know, genetic counselling, is that more of
a private, more expensive option, so might not be as
readily available.” (Female, average genomic risk)
Participants did express some concerns about the lim-
ited time that is typically available in GP consultations
and whether GPs had adequate knowledge and training
in genetics:
“I mean GPs are good at the general stuff of sun pro-
tection, but how good are they at going that little bit
step further as far as DNA is concerned? I’m not sure
about that.” (Male, average genomic risk)
Many felt that other health professionals such as
nurses or pharmacists could provide this type of infor-
mation, as long as they were equipped to do so:
“Well I think that you’d be giving it to people in the
medical profession or a pharmacist or someone with
experience in those areas with knowledge. See some
nurses would be fantastic, you know, but as long as
they’ve got a backup.” (Male, high genomic risk).
Discussion
This qualitative study explored a range of perspectives
on the potential opportunities and challenges for the
translation and incorporation of genomics-based disease
risk information into population prevention and screen-
ing strategies. Our findings align with the Genomic
Medicine Implementation Model, which emphasises the
importance of understanding the knowledge and beliefs
of otherwise healthy potential recipients of genomic risk
information [13].
We found that participants’ rationales for receiving
genomic risk information for themselves in the future
were based on their family history of disease and the
possibility of prevention or early detection for the condi-
tions. Previous studies conducted among healthy indi-
viduals undertaking genome sequencing in research
settings have found similar motivations [26, 27]. To date,
most research studies on genomic interventions have fo-
cussed on diet changes, smoking cessation and physical
activity, and have not found evidence of significant effect
on behaviour change. But these studies were limited by
high risk of bias and small sample sizes [28, 29]. On-
going research is examining the behavioural and psycho-
social impact of receiving personal genomic risk
information for conditions such as melanoma [30]. Our
qualitative findings in the current study highlight the im-
portance of providing support and education on preven-
tion and early detection alongside genomic risk
information.
Participants in our study were interested in receiving
personal risk information for conditions that they per-
ceived to be relatively common, particularly cancer, al-
though they were recruited via a cancer research
database. Another Australian study conducted among
cancer patients and their relatives found high enthusi-
asm for offering genome sequencing to the general
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population, prioritising those with a family history of
cancer [31]. In a population sample not selected for their
personal or family history of cancer, a Canadian study
found stronger support for population genomic sequen-
cing for colorectal cancer risk than type 1 diabetes, when
conducted alongside existing screening strategies [14].
They also found that public evaluations of the accept-
ability of population genomic sequencing depended on
the participants’ experiences of personal health decision
making and the availability of interventions to reduce
disease risk [14]. Other research has also shown that
perceived benefits of including genomic information in
population-based screening include the potential for
early detection, prevention and closer monitoring [32]. It
is important to note, however, that enthusiasm and opti-
mism regarding hypothetical genomic testing may not
necessarily translate into uptake of testing. This opti-
mism may also be based on an idealistic view of the
quality and benefits of genomic risk information, which
is frequently represented in popular social discourses
and mass media [33]. Factors such as ethnic minority
status may also influence public views towards testing
[34], although these were not explored in the present
study. Future research could explore the factors that in-
fluence actual uptake of population-based genomic se-
quencing, including whether and how individuals’ views
change after learning more about variability in data
quality.
Participants in our study proposed triaged approaches
to providing genomic risk information according to risk
levels, which supports our previous findings [35]. Simi-
larly, a cross-sectional study on United Kingdom women’s
attitudes towards tailored breast cancer screening based
on individual risk including genetic factors, found that let-
ters or emails were preferred for very low-risk results and
face-to-face communication was preferred for very high-
risk results [36]. GPs were the most commonly preferred
providers of face-to-face results [36]. In the present study,
participants felt that a health professional should be in-
volved in the information delivery process, even if only as
a point of contact for those who seek further communica-
tion. This aligns with other research findings that suggest
Australians are more comfortable seeking health-related
genetic information from a health professional compared
to a commercial company [37, 38]. However, some partici-
pants expressed a lack of trust in GPs providing genomic
risk information, as reported by others for personalised
breast cancer prevention information [39].
Participants also raised issues of access to genetic
counsellors and costs for the individual. If genomic risk
information is offered to the population, support or
provision for those tested may be accessed through
health professionals with genetic knowledge (for ex-
ample nurses trained in genomics) and alternative
modes should also be considered, such as genetic coun-
selling chatbots [40]. In countries such as Australia, the
genetic counselling workforce remains limited in size
and may be best accessed when pre- and/or post-test
counselling provision is required. Education of health
professionals will be crucial to ensure an informed
health professional workforce. Emerging research studies
are examining additional strategies to overcome feasibil-
ity and access issues, such as telephone genetic counsel-
ling [41, 42]. A research study is examining various
delivery models for the provision of predictive genetic
testing to the public in Europe and the US, Canada,
Australia and New Zealand [43]. The variability of health
systems and payment models will also likely influence
the provision of genomic risk information at the popula-
tion level. This may depend on whether offering gen-
omic risk information is incorporated into a formal
population screening program (which could be publicly
funded) or as a test offered in clinical practice (publicly
or privately funded). Considerations such as these will
impact workforce needs and training requirements, and
require further implementation research.
There are some limitations to the generalisability of our
findings. Participants in this study may have been particu-
larly optimistic about offering personal genomic risk infor-
mation to the general population because of their
participation in a pilot trial in which they received their
own personal risk. An advantage of this approach is that it
provided participants with a lived experience of receiving
genomic risk information, as opposed to relying only on
hypothetical scenarios. The interview questions did not
focus on specific diseases or existing screening programs,
and public views may differ according to these factors or
for diverse population subgroups. While these findings
focus on the Genomic Medicine Implementation Model
[13], there are other factors within and beyond this model
that influence the provision of genomic risk information
to the public, including referral visits, access, and costs.
Conclusions
In conclusion, participants thought it was acceptable to
provide personal genomic risk information to the gen-
eral population to inform prevention and early detection
recommendations, particularly for conditions such as
cancer, and where prevention strategies can be imple-
mented. They proposed tailoring the delivery of the per-
sonal risk information according to risk level, such that
people at higher risk could receive their information via
a genomics-trained health professional and those at
lower risk receiving written correspondence (letter or
email) with the option of contacting a health profes-
sional. These findings will contribute to implementation
strategies for incorporating genomic risk information
into population preventive healthcare.
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